Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease

NCT00491543 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Coronary Artery Disease

Interventions

DRUG: ALT-2074

Sponsor

Synvista Therapeutics, Inc